CSE PREV
LAST 0.04
CHANGE -0.01
OTC PRVCF
FSE 18H
CSE: PREV
LAST: 0.04
CHANGE: -0.01
OTC: PRVCF
FSE: 18H

PreveCeutical's Dr. Parekh and Dr. Khaled provide an update on our R&D programs

Network News Wire - Audio Interview with Stephen Van Deventer

Democracy in medicine - Financial Post Article

Proactive Investors Interview with Stephen Van Deventer - Video

Canadian med companies join to further research in Australia

PreveCeutical taps into wellness industry’s fastest growing segment

Gene Therapy Holds Out Hope for Diabetics

PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment - Video

A New Breakthrough in Cannabinoid Drug Delivery

Investment Opportunities in Advanced Bioengineered Drug Delivery

Promising New Approaches in Pain Management

Fast-Growing Cannabis Industry Drives Biotech Research, Innovative Medical Therapy Development

PreveCeutical Medical bidding to be big player in preventive healthcare

Market One Media/BNN interviews CEO Stephen Van Deventer - Video

PreveCeutical is poised for success with preventive health-care approach

Diabetes: Silence the Messenger, Don’t Shoot It!

Top 4 Companies Reinventing Cannabinoid Delivery

Entrepreneur “E-Radio” - Stephen Van Deventer Interview [00:18:21] - July 21, 2017

Winning the War on Diabetes & Obesity: a $2.5 Trillion Solution

PreveCeutical CEO Discusses Long-term Goals in Exclusive Interview

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange 

How PreveCeutical Medical Wants to Own a $3.8 Trillion Industry — Q&A with CEO Stephen Van Deventer

Cannabis, scorpions, and synthesizing better drugs

A Promising Delivery Platform for CBDs

PreveCeutical Medical Partners to Develop CBD Sol-Gels & Novel Diabetes Treatment, Plans to Go Public

Scorpion Venom Assists in Health and Wellness

Sign up for the latest news and updates